Updated S3 guideline irritable bowel syndrome with new bacterial strain:

B. bifidum MIMBb75, exclusively contained in Kijimea® Irritable Bowel Syndrome, has officially been included in the German S3 guideline for clinical practice

Gräfelfing, 31st August 2021. A big success for the patented bacterial strain of SYNformulas for the treatment of irritable bowel syndrome was achieved: The innovative bacterial strain B. bifidum MIMBb75, which is exclusively contained in Kijimea® IBS,  is now included in the recently updated and published “S3 guideline on the definition, pathophysiology, diagnostics and therapy of irritable bowel syndrome”. It is the only bacterial strain listed with significant effect on all four leading symptoms diarrhea, abdominal pain, flatulence, and constipation. The product Kijimea® IBS once again receives independent confirmation of its relevance in the therapy of irritable bowel syndrome. The bacterial strain B. bifidum MIMBb75 is exclusively contained in the product Kijimea® IBS and in its heat-inactivated form in Kijimea® IBS PRO.

The aim of the first revision of the S3 guideline adopted in 2010 is to compile the current state of knowledge on the still increasing clinical picture of irritable bowel syndrome, to evaluate new diagnostic and therapeutic options and to translate them into recommendations for clinical practice. The results serve as orientation in clinical practice and improve the outpatient and inpatient medical care of patients suffering from IBS. The S3 guideline is prepared with editorial independence by the DGVS, a German scientific expert association for digestive and metabolic diseases and the DGNM, the German association for neurogastroenterology and motility.

David Rietbrock, Managing Director of Synformulas GmbH: “We set ourselves the goal to advance the treatment of common diseases such as the irritable bowel syndrome by recommending selected probiotics and further expanding the acceptance of clinically proven therapy options. The inclusion of the bacterial strain B. bifidum MIMBb75 in the S3 guideline therefore honours us greatly and is a clear sign that Kijimea® IBS is a highly relevant therapy option: our patented bacterial strain is the only strain mentioned, which has a significant effect on all four leading symptoms of IBS.”

The bacterial strain B. bifidum MIMBb75 is used in the market-leading products Kijimea® IBS and Kijimea® IBS PRO and can significantly relieve the symptoms of IBS: diarrhoea, abdominal pain, flatulence, and constipation. This has been proven in two independent gold standard studies. The effect of Kijimea® IBS PRO, which contains the heat-inactivated bacterial strain B. bifidum HI-MIMBb75, was most recently proven in a study3 with 443 subjects in April 2020. The study results were published in the renomated medical journal The Lancet Gastroenterology & Hepatology.

Beitrag teilen:
About SYNformulas GmbH

SYNformulas is a globally leading probiotics company focused on researching the human microbiome and developing breakthrough, evidence based probiotics that significantly improve the quality of life. Under the brand Kijimea® the company's medical products, nutritional supplements and products for supplementary balanced diets are sold in ten countries on a pharmacy exclusive basis.SYNformulas achieved a breakthrough in the treatment of Irritable Bowel Syndrome: In two independent studies the patented bacterial strain B. bifidum MIMBb75, which is used for the products Kijimea® IBS and Kijimea® IBS PRO, showed significant efficacy in the widespread disease Irritable Bowel Syndrome and was most recently included in the S3 guideline Irritable Bowel Syndrome. For its pioneering product development with clinically proven efficacy, the company relies on an expert research & development team as well as cooperation with a broad network of internationally recognised researchers and universities.

SYNformulas is based in Gräfelfing close to Munich and is a subsidiary of the healthcare incubator FUTRUE, which operates internationally with over 20 companies.